Remove Biosimilars Remove Drug Research Remove International
article thumbnail

Innovation Drives Excellence, Innovent Successfully Held 2020 Virtual R&D Day

The Pharma Data

Liu shared his over 30 years of R&D experience in drug development both in the global pharmaceutical companies and world renowned scientific research institutions. By joining Innovent, Dr. Liu will be responsible for global R & D, pipeline strategy, business development and international operations.

article thumbnail

Article EMA Thank You What will the orphan drug market exclusivity haircut mean for industry?

Agency IQ

The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. Other orphan drugs, which, by definition, address an unmet medical need, “only” receive 9 years of market exclusivity.

article thumbnail

Article EMA Thank You What we expect European regulators to do in August and September 2024

Agency IQ

Positive August 2024 Balversa (erdafitinib) Janssen-Cilag International N.V. Positive September 2024 Yuvanci (macitentan / tadalafil) Janssen-Cilag International NV Positive September 2024 Eksunbi (ustekinumab)* Samsung Bioepis NL B.V.